Editas Medicine shares rise 10.53% premarket after EDIT-401 shows >90% LDL-C reduction in NHPs and extended cash runway.

Editas Medicine surged 10.53% in premarket trading following the announcement of robust preclinical data for its lead in vivo gene-editing candidate, EDIT-401, which demonstrated over 90% LDL-C reduction in non-human primates and durable effects in mice. The company also highlighted an extended cash runway into Q3 2027, reducing near-term financing risks and supporting the progression of EDIT-401 toward an IND/CTA submission by mid-2026. The positive preclinical results, coupled with improved Q3 financials—including a narrower net loss and revenue exceeding estimates—reinforced investor confidence in the therapy’s potential as a one-time treatment for LDL cholesterol reduction.